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Purpose: To assess the safety and outcomes of radiotherapy (RT) or chemoradiotherapy (CRT) in elderly patients
(≥70) with rectal cancer.
Methods: Elderly patients aged 70 and older with rectal cancer, who were treated with RT or CRT at a single
institution, were retrospectively analyzed. Performance status (KPS and ECOG score) and comorbidity (Charlson
comorbidity index) were calculated, and their correlation with treatment toxicity and overall survival were studied.
Risk factors for overall survival were investigated using univariate and multivariate survival analysis.
Results: A total of 126 patients with locally advanced disease, local recurrence or synchronous metastasis were
included, with a 3-year OS rate of 48.1%. Scheduled dosage of radiation was delivered to 69% of patients. Grade 3
toxicities occurred more often in patients treated with CRT versus RT. The occurrence of grade 3 toxicities was not
related to KPS score, ECOG score, number of comorbidities, and Charlson score. Multivariate analysis found that
only age and Charlson score were independent prognostic factors for predicting patients’ 3-year OS. The 3-year OS
rate was significantly higher in patients with Charlson score <4 vs Charlson score ≥4 (71.1% vs. 26.4%, P=0.0003).
Conclusions: Although toxicities may be significant, elderly patients with rectal cancer of varied stages can be
safely treated with RT or CRT with careful monitoring and frequent modification of treatment. Except for patients’
age, Charlson comorbidity index may be helpful in assessing patients’ outcomes in elderly patients with rectal
cancer.
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Colorectal cancer (CRC) is the fifth most common malig-
nancy in China. As the population ages, more and more
elderly patients are diagnosed with CRC. In Shanghai, one
of the most developed areas of China, patients older than
70 years accounted for 57% of all newly diagnosed colo-
rectal cancers in 2006, compared with only 32% in 1990
[1]. Determining the optimal treatment for elderly patients
with CRC is a complex process, especially in rectal cancer.
Elderly patients are more likely to have other concomitant* Correspondence: caisanjun@gmail.com
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reproduction in any medium, provided the orchronic illnesses (comorbidity), which may increase the
risk of complications and even death during treatment.
When treating elderly patients with rectal cancer, it is vital
to determine how aggressively to treat, so that the costs
and risks of the treatment will not outweigh the short-
term benefits from treatment of the cancer. Recent studies
have confirmed the survival benefit of adjuvant chemo-
therapy in elderly patients (≥75 years) with resected colon
cancer [2]. However, the value of chemoradiotherapy
(CRT) or radiotherapy (RT) in elderly patients with rectal
cancer is still controversial. In addition to patients’ comor-
bidity, several factors including the higher morbidity rate
of rectal cancer surgeries, stoma related complications,
and the toxicity of RT or CRT, are also responsible for the
limited use of standard treatment in elderly patients with
rectal cancer.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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luate the outcomes and safety of treatment in elderly pa-
tients, including patients’ performance status (Karnofsky
Performance Status Score [3] and ECOG Performance
Status Score [4]) and comorbid conditions (Charlson co-
morbidity index [5]). The purpose of the current study
was to assess the safety of RT or chemoradiotherapy in
elderly patients (≥70 years) with advanced rectal cancer,
and to evaluate the value of comorbidity index in pre-
dicting patients’ survival.
Material and methods
Patient and treatment protocol
A retrospective study was performed. We reviewed the
hospital records of consecutive patients aged 70 years
and older with rectal cancer who were treated in the
Department of Radiological Oncology, Fudan University
Shanghai Cancer Center between January 2002 and
December 2010. All patients had histologically confirmed
adenocarcinoma, and all tumors were located <12 cm
from the anal verge as confirmed by colonoscopy or digi-
tal examination.
In our series, the patients could be categorized into 3
groups according to their treatment purpose: 1) Curative
intent treatment: patients undergoing surgical resection
of primary tumor with neoadjuvant or adjuvant RT or
CRT; 2) Local control: patients with local recurrence or
major comorbidity that were unsuitable for surgical re-
section; 3) Symptom control: patients with symptomatic
primary tumor and unresectable synchronous distant
metastases.
The treatment strategies and dosage of RT or chemo-
therapy were determined by comprehensive assessment
of patients' tumor stage, age, performance status, comor-
bidity, and history of medication. RT treatments were
performed according to institutional protocols. Conven-
tional RT was used in all of the patients. The mean total
dose of RT was 52.2Gy (50.4Gy in curative intent group,
53.8Gy in local control group, 52.6Gy in symptom con-
trol group), ranging from 30Gy to 66Gy.
Treatment toxicity, performance status and comorbidity
During treatment, patients were monitored weekly for
signs of acute toxic effects, with corresponding adjust-
ments in chemotherapy regimens and RT protocols. Acute
treatment-related toxicities were evaluated using the
National Cancer Institute Common Toxicity Criteria
for Adverse Events (CTCAE v3.0) [6]. Diarrhea, skin
toxicity and neutropenia were the major evaluated ef-
fects in the current study.
Patients’ performance status was assessed by Karnofsky
Performance Status Score (KPS Score) [3] and ECOG Per-
formance Status Score (ECOG Score) [4]. Patients’ comor-
bidity was rated according to Charlson Comorbidity IndexScore (Charlson Score) [5]. As the stage of primary tumor
varied from stage I to stage IV in our series, the scores of
baseline cancer disease were also calculated in Charlson
score. The scoring algorithm for cancer is as follows: two
points were scored in patients with primary tumor in situ,
zero points were scored when primary tumor was surgi-
cally resected, and six points were scored in patients with
distant metastases. As Charlson score does not specify the
point score for local recurrence in rectal cancer, 6 points
were scored for local recurrence because of similar overall
survival compared with patients with distant metastases in
our series (shown in Results).
Statistics
Chi-square test and t-test were used to compare the
rates of early toxicity between different treatment mo-
dalities, performance status (KPS and ECOG score) and
comorbidities (Charlson Score). Three-year survival rate
was used as the endpoint in outcome analyses. The
Kaplan-Meier method was used to calculate overall survi-
val rates with the log-rank test. Cox proportional hazards
regression was used in univariate and multivariate ana-
lyses. P<0.05 was considered statistical significant.
Results
A total of 126 patients aged 70 years and older were in-
cluded in current study. The median age was 75 years
old (range 70–92 years), with 58% of patients aged 75
years and older. 51 cases (40.5%) were treated with cura-
tive intent by surgical resection with adjuvant or neo-
ajuvant RT/CRT. 47 patients (37.3%) were treated for
local control, of which 33 patients were radiated due to
local recurrence, and the other 14 patients were radiated
alone due to major comorbidities. Out of 73 patients
with concurrent CRT, 37 patients were treated with com-
bination chemotherapy and 36 patients had single agent
chemotherapy with 5-FU or capecitabine. Patients’ clinico-
pathological characteristics are listed in Table 1.
Performance status, comorbidity and early toxicity
Planned dosage of RT was delivered to 69% of patients.
Dose modification or discontinuation of chemotherapy
was required in 37.3% of patients. None of the patients
in our series had grade 4 toxicities. The overall rate of
grade 3 toxicity was 34.9%; with a rate of 8.7% in RT only
group and 26.2% in the CRT group (P=0.004). Grade 3
diarrhea, skin toxicity and neutropenia were observed in
14.2%, 17.5%, and 7.9%, of patients.
90.4% of patients had a KPS score >80 and 79.4% of
patients had an ECOG of 0 or 1. The median Charlson
score was 4, ranging from 0 to 8. The occurrence of grade
3 toxicity was not related to patients’ age (< 80 years vs. 80
years and older, P=0.326), KPS score (P=0.90), ECOG
Table 1 Clinicopathological features of 126 elderly
patients with rectal cancer









Primary only 65 51.6
Local recurrence 33 26.2



















Curative Intent Treatment 51 40.5
Local control 47 37.3
Symptom control 28 22.2
Modality of RT
RT only 53 42.1
CRT 73 57.9
*abbreviation: RT, Radiotherapy; CRT, Chemoradiotherapy.
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Charlson score (P=0.729).
Outcome and prognostic factors
With a median follow-up time of 19 months, the 3-year
OS rate was 48.1% for all patients. The 3-year overall
survival rates were 81.5%, 30.8% and 13.7% in patientswith curative intent treatment, local control and symp-
tom control, respectively.
Three-year OS rate was significantly higher in patients
with primary tumor only than in patients with local re-
currence or synchronous distant metastases (68.3% vs.
22.3%, P=0.001), while the 3-year OS rates were similar
between patients with local recurrence and with syn-
chronous distant metastases (3-year OS: 32.5% in local
recurrence group vs. 13.7% in synchronous distant me-
tastases group, P=0.17). Considering the similar out-
comes, we scored 6 points in Charlson Comorbidity
Index for patients with local recurrence, equal to the
score for distant metastases.
Univariate analyses were performed for the entire
series to screen potential factors which predict overall
survival in elderly patients, including gender, age, disease
status, treatment modality, occurrence of early grade 3
toxicity, KPS score, ECOG score and Charlson score. Pa-
tients’ age, disease status and Charlson score were found
to be potential prognostic factors for OS (Table 2).
Multivariate analysis revealed that only age and
Charlson score were independent prognostic factors
for predicting patients’ 3-year OS. The hazard ratios
were 1.12 (95% CI 1.06-1.20, P=0.0001) and 1.20 (95%
CI 1.06-1.35, P=0.003), respectively. Subgroup analyses
found the 3-year OS rate was 62.4% in patients aged
70–79 years, compared with 6.1% in patients aged 80
years and older (P<0.001, Figure 1). As the median
value of Charlson score was 4, we classified patients
into two groups (<4 vs. ≥4). The 3-year OS rate was
significantly higher in patients with Charlson score <4
than Charlson score ≥4 (71.1% vs. 26.4%, P=0.0003,
Figure 2).
Discussion
Establishing a treatment strategy for elderly patients
with rectal cancer is a difficult process. Meta-analysis of
randomized studies has shown the benefit of RT in local
control regardless of patients' age [7]. However, the im-
provement in overall survival due to RT is still contro-
versial. Studies from two population based cohorts in
the Netherlands and the Dutch Trial showed that pa-
tients aged 75 years or older had significantly lower
overall survival and higher mortality within 6 months
after treatment than patients younger than 75 years.
Meanwhile, no survival improvement was observed with
the introduction of standard preoperative RT/CRT and
surgical resection in patients more than 75 years old [7].
It is important for clinicians to select optimal treat-
ment modalities in elderly patients with rectal cancer
by careful assessment of patients' outcomes, treatment
risks, life expectancy and comorbidities. Higher rates
of surgical complications, more prevalent co-morbidities,
and poorer performance status limit the standard use of
Table 2 Univariate analyses for outcomes in elderly patients with rectal cancer
Characteristics No. (n=126) Hazard ratio 95% CI P value
Gender
Male 84
Female 42 1.14 0.61–2.13 0.685
Disease
Primary tumor only 65
Local recurrence 33 2.28 1.03–5.05 0.042
Synchronous Metastasis 28 3.91 1.89–8.09 0.0002
Treatment mode
RT 53
CRT 73 0.97 0.52–1.81 0.92
Grade 3 toxicity
No 82
Yes 44 1.48 0.73–3.02 0.281
Continuous variables
Age 126 1.13 1.07–1.20 0.00002
KPS Score 126 0.99 0.95–1.02 0.558
ECOG Score 126 1.42 0.93–2.17 0.103
Charlson Score 126 1.21 1.09–1.36 0.001
*abbreviation: RT, Radiotherapy; CRT, Chemoradiotherapy; CI, Confidence Interval.
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ment deviation is higher in elderly patients than younger
patients [8-10]. Margalit et al. reported an 83% rate of
early treatment termination, treatment interruption, or
dose reduction in patients aged 75 years and older [11].
Aparicio et al. also reported only 37.5% (9 out of 24) of pa-
tients aged 75 years and older with locally advanced rectal
cancer received RT after surgery [12]. In our series of pa-
tients treated with RT or CRT, dose reductions of RT and/




















Aged 80 and older
Figure 1 Difference in overall survival rates of patients aged
70–79 years vs 80 and older.patients. Although none of these patients had grade 4
toxicities, almost one-third of patients had grade 3 toxic-
ities, which may be the main factor causing treatment
dose reduction. Careful monitoring and frequent modifi-
cation of treatment were necessary when RT or CRT was
used in patients aged 70 or older with rectal cancer. Our
study provides useful insight into the tolerability of RT or
CRT in a variety of elderly patients with rectal cancer, in-






















Figure 2 Difference in overall survival rates of patients with
Charlson score <4 vs Charlson score ≥4.
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patients' general well being and activities of daily life.
Two kinds of performance status scale system, the
Karnofsky score and ECOG score, are widely used in ran-
domized clinical trials to evaluate patients’ pre-treatment
status or measure quality of life. However, most patients
were had relative good performance status and fewer
comorbidities when receiving cancer-specific treatment. It
is difficult to evaluate the value of performance status or
comorbidities in predicting treatment toxicity. Currently,
performance status scales are mainly used to determine
whether patients are eligible for initiating a certain treat-
ment. It had been reported that the use of adjuvant
chemotherapy for patients with stage III colon cancer
markedly decreased with rising age and comorbidity [13].
In this study, there was no association between patients'
performance status or comorbidity and treatment toxic-
ities. The cause may be sub-standard dosage of chemo-
therapy or RT during treatment, which may minimize the
occurrence of grade 3 toxicities.
Currently, the data on combined therapies for rectal
cancer used in elderly patients are limited. From analysis
of the SEER registry data for a large number of patients,
the cancer-specific survival rates in rectal cancer decrease
as patient age increases. Oncologically, the decreased use
of any cancer directed treatment, an increased use of local
treatment, and a decreased use of radical surgery as the
patients’ age increased may be attributed to this [14].
However, the SEER registry data cannot be used to eva-
luate the impact of comorbidities on survival of elderly pa-
tients with rectal cancer. Population-based studies have
demonstrated that increased age and comorbidity were
important prognostic factors for the survival of cancer
patients [15,16]. In our study, a significantly decreased of
3-year survival was also observed in patients aged 80 or
older. This negative influence of comorbidity on survival
of cancer might be due to the increased risk of death due
to the comorbid conditions, more contraindications for
anti-cancer treatment, more indications for dose reduc-
tion and a higher rate of treatment-related complications
(infections and cardiovascular events). Other studies have
found the effect of comorbidity to be independent of
treatment; so sub-standard treatment may not fully
account for shorter survival in patients with comor-
bidities [13,17,18].
The Charlson comorbidity index is a method of pre-
dicting mortality by classifying or weighting comorbid
conditions (comorbidities) [5]. It has been widely utilized
and validated by health researchers for its ability to pre-
dict mortality in various disease subgroups, including
cancer, renal disease, stroke, intensive care, and liver di-
sease [19-21]. However, the prognostic value of Charlson
score in combined treatment of rectal cancer is still
unclear. Higher Charlson score was found to be anindependent risk factor for poor overall survival in
patients with colorectal cancer [12], while other studies
did not find a survival difference [22,23]. Charlson score
has been used in many studies after modification by neg-
lecting the score of baseline disease like cancer [12,22].
However, since a variety of patients with different stages
of rectal cancer were studied in our series, it was reason-
able to incorporate the score of solid cancer (scoring 2 for
solid cancer and 6 for metastasis) into the score of con-
comitant comorbidity. Multivariate analysis demonstrated
the value of age and Charlson score in independently
predicting patients overall survival in stage I-IV rectal can-
cers. Significantly decreased overall survival was observed
in patients with Charlson score≥4. As we incorporated
tumor stage into Charlson score, our study provides a
simple method to evaluate the outcomes of patients aged
70 or older with varied stages of rectal cancer.
It should be mentioned that we did not perform a
relapse-free survival or a cancer specific survival because
information on relapse was not clearly obtained in this
retrospective study. Some studies have shown that per-
formance status and co-morbidity are both independent
prognostic factors [24,25], which therefore may both
need to be included in future prognostic studies. Add-
itional factors beside comorbidity may better predict
treatment deviation in elderly patients. The International
Society for Geriatric Oncology advocates the use of a
comprehensive geriatric assessment (CGA) tool to iden-
tify baseline factors that may influence treatment toler-
ability [26]. Studies have shown the ability of CGA in
predicting the risk of chemotherapy toxicity and cancer
treatment-related morbidity and mortality [27,28]. Other-
wise, our study was a retrospective study with a small vo-
lume of patients and various treatment regimens; it was
difficult to clearly conclude the importance of a certain
prognostic factor to select treatment regimens. However,
our study addressed an important question regarding the
toxicities of RT for elderly patients with rectal cancer, and
we also provide a preliminary insight to integrate co-
morbidity scoring system to survival analysis in elderly pa-
tients. Further randomized clinical trials were needed for
these patients.
In conclusion, although the toxicity of RT or CRT was
high in patients aged 70 and older, RT or CRT can be
safely delivered with careful monitoring and frequent
modification of treatment in elderly patients with rectal
cancer of varying stage. Patients' age and Charlson score
were independent prognostic factors for survival in pa-
tients aged 70 and older. Charlson comorbidity score
may be helpful in assessing patients’ outcomes in elderly
patients with rectal cancer.Competing interests
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